Purple Biotech (NASDAQ:PPBT – Get Free Report) and Silverback Therapeutics (NASDAQ:SBTX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.
Valuation & Earnings
This table compares Purple Biotech and Silverback Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Purple Biotech | $1.00 million | 22.32 | -$21.67 million | ($1.10) | -0.97 |
| Silverback Therapeutics | N/A | N/A | -$89.48 million | ($2.42) | -2.43 |
Purple Biotech has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Purple Biotech | 0 | 0 | 3 | 0 | 3.00 |
| Silverback Therapeutics | 0 | 0 | 0 | 0 | N/A |
Purple Biotech presently has a consensus target price of $9.33, suggesting a potential upside of 772.27%. Given Purple Biotech’s higher possible upside, equities analysts plainly believe Purple Biotech is more favorable than Silverback Therapeutics.
Profitability
This table compares Purple Biotech and Silverback Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Purple Biotech | N/A | -42.98% | -37.92% |
| Silverback Therapeutics | N/A | -29.62% | -28.20% |
Institutional & Insider Ownership
7.2% of Purple Biotech shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Purple Biotech has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
Summary
Purple Biotech beats Silverback Therapeutics on 7 of the 11 factors compared between the two stocks.
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
About Silverback Therapeutics
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Purple Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Purple Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
